A broad goal of my laboratory is to integrate the pathophysiology of a disease state with the known pharmacology of drugs to develop optimal delivery systems for existing and novel therapies for cancer and translate those findings from discovery and preclinical development to clinical use. Specifically, my research interests are in optimizing drug dosing schedules and developing nanomedicines, and exploiting such drug carriers for the treatment of primary and metastatic cancer. We have a specific interest in the development and combination of vascular targeting and conventional oncolytic agents to induce immediate tumor regression and/or facilitate long-term tumor dormancy. Our primary aims are to (i) determine the direct anti-tumor effect and ability of novel nanoparticulate drug carriers to limit tumor growth and metastases in vivo, (ii) gain insights into the molecular mechanisms of the antitumor/vascular effects following acute (high-dose) and chronic treatement (low-dose, protracted treatment), (iii) develop a mechanistic understanding of how long-circulating nanoparticulate drug carriers can be used and optimized to enhance conventional antitumor activity while mediating novel antivascular or antiangiogenic effects, (iv) examine the use of existing and novel tumor/vascular molecular targeting moieties, and (v) develop mathematical expressions (PK/PD-modeling) to describe drug exposure–response relationships, and use them to predict optimal drug dosing schedules.